Tatva Chintan Pharma Chem logo

Tatva Chintan Pharma Chem financials: balance sheet, profit and loss, cash flow

NSE: TATVABSE: 543321Chemicals & PetrochemicalsSmall Cap

Tatva Chintan Pharma Chem Limited · Face value ₹10 · Listed Jul 2021 · Issue price ₹1,083
Last close ₹1,643.90up ₹29.10 (1.80%)BSE ₹1,645.45

Share price at the NSE close on 30 Oct 2026. Previous close ₹1,614.80.

30 Oct: open ₹1,624.90, high ₹1,659.00, low ₹1,582.10

52-week range of traded prices to 30 Oct 2026
₹1,044.10Low, 30 Mar 2026₹2,113.60High, 21 Oct 2026
Market cap
₹3,845 Cr999th largest listed
P/E
61.12
P/B
4.72
Dividend yield
0.12%
ROE
8.0%
ROCE
8.8%
Debt to equity
0.21
Volume, NSE
74,35445.2% delivered

Tatva Chintan Pharma Chem's financial statements for the 5 years to Mar 2026, consolidated: the company and its subsidiaries together, with the half year to Sep 2026 after them.

5 years at a glance

₹ crore, years to March.Tatva Chintan Pharma Chem annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
43496120Mar 2242445170Mar 233943014Mar 243835.736Mar 2550642120Mar 26
Peak revenue ₹506 Cr, year to Mar 2026; lowest ₹383 Cr, year to Mar 2025

Operating and net margin, per cent

  • Operating margin
  • Net margin
25.0%1.5%25.0%14.3%17.3%8.9%18.4%22.1%10.7%7.7%1.5%8.3%Mar 22Mar 23Mar 24Mar 25Mar 26

Results for the year to Mar 2026

Consolidated: the company and its subsidiaries together. ₹ crore.

From revenue to net profit

  1. Revenue506
  2. Materials and goods−225
  3. Employee costs−63
  4. Other expenses−125
  5. Operating profit93
  6. Depreciation−37
  7. Other income+3.5
  8. One-off items0.0
  9. Finance costs−2.9
  10. Profit before tax57
  11. Tax−15
  12. Net profit42

What the company owns

  • Plant, investments and other assets₹680 Cr
  • Inventory₹196 Cr
  • Receivables₹119 Cr
  • Cash and bank₹9 Cr

What pays for it: net worth and liabilities

  • Net worth₹782 Cr
  • Borrowings₹120 Cr
  • Owed to suppliers₹58 Cr
  • Other liabilities₹43 Cr

Profit and loss

Consolidated, ₹ crore, years to March. The last column is the twelve months to Sep 2026, the latest four quarters added.Tatva Chintan Pharma Chem quarterly results

₹ croreMar 2022Mar 2023Mar 2024Mar 2025Filed 2 MayMar 2026Filed 16 MaySep 2026Twelve monthsFiled 19 Oct
Revenue from operations434424394383506650
325363325349413523
Materials and goods bought195226174199225293
Employee costs313955536369
Other expenses100989697125162
Operating profit before depreciation10861683493127
Operating margin25.0%14.3%17.3%8.9%18.4%19.5%
Materials, % of revenue44.9%53.4%44.3%52.0%44.4%45.1%
Employee costs, % of revenue7.1%9.1%13.9%13.8%12.4%10.6%
Other expenses, % of revenue23.0%23.2%24.5%25.3%24.8%24.9%
Depreciation and amortisation81026283740
Operating profit after depreciation100514375686
Other income968246
Finance costs587137
Profit before one-off items and tax104484485786
One-off items0−4000−1
Profit before tax104454485784
8−11321521
Net profit96453064263
Other comprehensive income010132
Total comprehensive income96463064565
Net margin22.1%10.7%7.7%1.5%8.3%9.7%

Balance sheet

Consolidated, ₹ crore, at 31 March. The last column is the half year to Sep 2026, after the latest full year: the balance sheet at its end.

₹ croreMar 2022Mar 2023Mar 2024Mar 2025Filed 2 MayMar 2026Filed 16 MaySep 2026Half yearFiled 19 Oct
473515737739782815
Share capital222223232323
Reserves451493714715758791
1201701436120170
1712368096213296
1452199
Total assets6587568198361,0041,119
222443521571654650
436314298265350469
Net debt−57125−3422112155
Borrowings are counted again inside the liabilities due within a year and after a year. Plant in use and plant being built are given for full years only.

Cash flow

Consolidated, ₹ crore, years to March. The last column is the half year to Sep 2026, after the latest full year: the cash flow over its six months.

₹ croreMar 2022Mar 2023Mar 2024Mar 2025Filed 2 MayMar 2026Filed 16 MaySep 2026Half year
2028982531−4
393710829391
−75−2836−8−62−73
Receivables34−3115−15−22−64
Inventories−9871019−62−53
Payables−3−1311−132033
Other working capital−88−12211
Tax paid−18−9−10−4−8−4
Capital spending892031297611431
Free cash flow−69−175−30−52−82−35
−197−101−121−65−116−31
2353831177940
Dividends paid045525
Shares bought back000000
Shares issued2110197000
Net change in cash59−368−24−55
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only.

Per share

Consolidated, ₹ per share, years to March.Tatva Chintan Pharma Chem dividend history

₹ per shareMar 2022Mar 2023Mar 2024Mar 2025Filed 2 MayMar 2026Filed 16 May
Earnings per share₹44.59₹20.52₹13.26₹2.44₹17.98
Diluted earnings per share₹44.59₹20.52₹13.26₹2.44₹17.98
Dividend per share₹2.00₹2.00₹2.00₹1.00₹2.00
Book value per share₹213.44₹232.25₹315.10₹315.84₹334.20
Dividend payout4.6%9.7%15.4%40.9%11.1%
Shareholder yield−4.1%0.1%−7.6%0.3%0.1%
Market cap at the year end (₹ crore)5,1173,6992,5231,5842,462

Ratios

Consolidated, years to March.Tatva Chintan Pharma Chem PE ratio and valuation

RatioMar 2022Mar 2023Mar 2024Mar 2025Filed 2 MayMar 2026Filed 16 May
Revenue growth–−2.3%−7.1%−2.7%32.2%
Operating profit growth–−44.0%12.6%−49.8%172.3%
Net profit growth–−52.6%−33.3%−81.2%636.1%
Earnings per share growth–−54.0%−35.4%−81.6%636.9%
20.3%9.2%4.8%0.8%5.5%
–−11.1 pts−4.4 pts−4.1 pts4.8 pts
From the net margin–−10.4 pts−2.6 pts−3.9 pts3.5 pts
From asset turnover–−0.9 pts−1.1 pts−0.1 pts0.8 pts
From borrowing–0.3 pts−0.7 pts−0.1 pts0.4 pts
Return on capital employed16.9%7.4%5.7%0.8%6.2%
Cash conversion21.3%61.1%323.0%431.8%74.9%
Interest cover20.76.16.55.119.8
Debt to equity0.250.330.020.050.15
Receivable days4873657986
Inventory days319262320246319
Payable days8352946095
Cash conversion cycle, days283283291264310
Working capital days164171170183175
Asset turnover0.660.600.500.460.55
Assets per rupee of net worth1.391.431.261.121.21
Sales per rupee of plant2.722.160.920.730.84
Capital spending to depreciation10.9021.265.022.763.09
Plant being built, % of plant in use32.3%117.9%17.1%4.1%3.9%

Growth and returns over 3, 5 and 10 years

Consolidated: the company and its subsidiaries together. Each window ends with the year to Mar 2026.

Return on assets, latest year
4.6%
Cash from operations against operating profit
33.8%
Measure5 years3 years
Revenue growth, yearly rate–6.1%
Profit growth, yearly rate–−2.6%
Return on equity, average8.1%3.7%
Return on capital employed, average7.4%4.3%
Operating margin, average16.8%14.9%
Net margin, average10.1%5.8%
Asset turnover, average0.550.50
Cash conversion cycle, days, average286288
Interest cover, average11.610.5
Debt to equity, average0.160.07

Where the cash came from and went

Consolidated: the company and its subsidiaries together. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ crore5 years3 yearsLatest year
Cash from operations20215431
Cash from investing−600−302−116
Cash from financing39912679
Capital spending611319114
Dividends paid16122
Shares bought back000
Shares issued for cash4081970
Borrowings raised––85
Borrowings repaid40121

Accounting checks

Consolidated, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Piotroski score, out of 9Published threshold 3 points out of 9––656
Altman Z-scorePublished threshold 1.8119.2211.0220.7711.698.58
Beneish M-scorePublished threshold −1.78–−0.92−3.17−2.65−2.56
Profit not backed by cash, % of assetsPublished threshold 10 per cent of average total assets–16.806.715.5913.74
Cash from operations to profit, 3 yearsPublished threshold 0.7 times––0.851.851.97
Receivables growth less revenue growthOur threshold 0 percentage points–51.44−10.1320.8912.06
Inventory growth less cost-of-goods growthOur threshold 0 percentage points–−20.5516.97−26.5333.51
Other current assets growth less revenue growthOur threshold 5 per cent of revenue–−2.471.272.02−1.79
Assets under construction, years of additionsOur threshold 2 years of additions–5.010.280.170.20
Effective tax ratePublished threshold 17.16 per cent7.92−1.5830.3324.6226.23
Tax charged less tax paid, % of profitOur threshold 10 percentage points−9.76−22.337.70−34.7312.76
A threshold marked as ours has no published figure; it is the line we read the check against.

Credit ratings

An agency's view of the chance the company repays a borrowing on time, from AAA, the highest, down to D, in default.

DateAgencyBorrowing ratedRatingOutlookAmount, ₹ Cr
8 Sep 2026CRISIL Ratings LimitedBank FacilitiesCrisil A2+Review, Upgrade10.50
8 Sep 2026CRISIL Ratings LimitedBank FacilitiesCrisil A-Review, UpgradeStable220
The latest rating on each borrowing. The agency's name opens its reasoning for the rating.